What is the price of Napavir sodium (Sunlenca) in 2025?

Lenapavir sodium/Sunlenca (Sunlenca) has become an important representative of the new generation of HIV-1 integrase inhibitors since it was approved by the US FDA in December 2022. The drug is also available in the domestic market and is mainly available in two dosage forms: tablets and injections. The tablet specification is 300mg 5 tablets, and the injection specification is 463.5mg/1.5ml 2 tubes. In terms of price, since the drug is an innovative original drug, the market price is relatively high. A box of tablets sells for about 50,000 yuan, while a box of injections sells for about 100,000 yuan. Due to its short time on the market, it has not yet been included in the scope of domestic medical insurance reimbursement, and purchase channels are relatively limited.

Lenapavir sodium is mainly used to treat HIV infection (AIDS) adult patients, especially for patients with multi-drug-resistant virus strains or patients who are intolerant to other antiviral drugs. Its pharmacological effect is to inhibit the activity of HIV integrase and prevent the integration of viral genes into host cell DNA, thereby effectively blocking the viral replication chain. By reducing plasma viral load and maintaining CD4+ cell levels, lenapavir sodium can improve patients' immune function and delay the development of complications related to HIV infection.

In clinical use, lenapavir sodium can be used as a single agent or as part of combined antiviral therapy, combined with other reverse transcriptase inhibitors or protease inhibitors to enhance efficacy and delay the emergence of drug resistance. The drug's oral tablet form facilitates long-term administration by patients in a home setting, while its injectable form is suitable for rapid-acting antiviral treatment given in hospital or clinical settings.

Since lenapavir sodium is an original and innovative drug, it has a high price and is not yet covered by medical insurance, which means that patients may need to bear higher economic costs in the early stages of treatment. Therefore, doctors usually evaluate the most appropriate treatment plan based on the patient's viral load, drug resistance, and financial affordability when prescribing.

Reference materials:https://www.drugs.com/sunlenca.html